To amend section 495 of the Public Health Service Act to require inspections of foreign laboratories conducting biomedical and behavioral research to ensure compliance with applicable animal welfare requirements, and for other purposes.

HR7165, titled 'To amend section 495 of the Public Health Service Act to require inspections of foreign laboratories conducting biomedical and behavioral research to ensure compliance with applicable animal welfare requirements, and for other purposes,' was introduced in the House on January 20, 2026. It was subsequently referred to the House Committee on Energy and Commerce on the same day. This bill is in its early legislative stage, with only two cosponsors, indicating limited momentum at this time. The bill's sponsor is Rep. Steube, W. Gregory [R-FL-17]. This bill does not authorize or appropriate any specific funding amount. Instead, it proposes a new regulatory requirement: mandatory inspections of foreign laboratories conducting biomedical and behavioral research. This requirement would directly increase operational costs for companies that rely on these foreign facilities. The mechanism of impact is through compliance costs, administrative overhead, and potential delays in research and development timelines due to inspection processes. Structural losers under this proposed legislation include Contract Research Organizations (CROs) and pharmaceutical companies with significant international research operations. Specifically, companies like IQVIA Holdings Inc. ($IQV) and Charles River Laboratories International, Inc. ($CRL) are identified as directly impacted due to their business models involving global research services. Pharmaceutical companies such as Pfizer Inc. ($PFE), Johnson & Johnson ($JNJ), and Merck & Co., Inc. ($MRK), which often outsource or conduct research in foreign laboratories, would also face increased costs and potential delays in their drug development pipelines. The bill's current status as 'Referred to committee' means it must advance through committee, potentially be voted on by the House, then move to the Senate, and finally be signed by the President to become law. Looking at recent market data, IQVIA Holdings Inc. ($IQV) is currently at $170.72, showing a +2.74% gain over the last 7 days but a -4.36% decline over the last 30 days. Charles River Laboratories International, Inc. ($CRL) is at $168.22, with a +5.32% gain over 7 days but a -7.22% decline over 30 days. Pfizer Inc. ($PFE) is at $27.83, with a +0.22% gain over 7 days and a +4.58% gain over 30 days. Johnson & Johnson ($JNJ) is at $240.97, with a -0.63% decline over 7 days and a +0.56% gain over 30 days. Merck & Co., Inc. ($MRK) is at $120.85, showing a +2.33% gain over 7 days and a +4.12% gain over 30 days. While the 7-day performance for IQV and CRL shows some positive movement, their 30-day performance is negative, indicating some recent downward pressure that predates or is unrelated to the bill's introduction. The pharmaceutical companies show mixed performance over these periods. Given its early stage, the timeline for HR7165 is uncertain. It must first be considered by the House Committee on Energy and Commerce. If it passes committee, it would then proceed to a vote in the full House. Should it pass the House, it would then move to the Senate for consideration, where it would undergo a similar committee and floor vote process. Finally, presidential assent would be required for it to become law.